Pulike Biological Engineering, Inc. is a state-level high-tech enterprise mainly engaged in the R&D, production, and marketing of veterinary biological products and drugs. Its innovative ability and comprehensive strength rank among the top in the industry. Pulike has 7 wholly-owned subsidiaries: Luoyang Huizhong Biological Technology Co., Ltd., Luoyang Huizhong Animal Medicine Co., Ltd., Henan XinZhengHao Bioengineering Co., Ltd., Luoyang Zhongke Science Technology Park Co., Ltd. and Pulike (NJ) Biological Technology Co., Ltd., Luoyang Huiizon Animal Health Co., Ltd., Luoyang Lepet Health Technology Co., Ltd. Pulike is a listed company on the Shanghai Stock Exchange (stock code: 603566), a vice-chairman unit of China Animal Husbandry and Veterinary Medicine Association, a vice-chairman unit of China Veterinary Medicine Association, and a national technological innovation demonstration enterprise.

We are the vice-chairman unit of the National Veterinary Drug Industry Technology Innovation Alliance, the National Pig Industry Technology Innovation Alliance, and the National Animal Health Management and Food Safety Innovation Alliance.

Pulike has always considered innovation to be the source of power for enterprise development. Pulike has the National Research Center for Veterinary Medicine （NVC）approved by the Ministry of Science and Technology, the National Enterprise Technology Center jointly approved by the National Development and Reform Commission and the Ministry of Science and Technology and other five ministries and commissions, and the national and local joint engineering laboratory for the development of diagnostic reagents and vaccines for animal infectious diseases approved by the National Development and Reform Commission. The research and development center covers an area of ​nearly 20,000 square meters, with more than 200 technical research and development staff with doctoral and master's degrees as the mainstay. It has successively established extensive industry-university-research cooperation with the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences, Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences, Institute of Microbiology of the Chinese Academy of Sciences, Military Veterinary Research Institute of Chinese Academy of Medical Sciences, China Agricultural University, Nanjing Agricultural University and other institutions. Pulike has always maintained high-intensity investment in R&D; in recent years, the proportion of R&D expenses in operating income has consistently remained above 10%.

Based on the company's strong innovation capabilities and relying on a research and development platform built with high standards and a high starting point, the company has successively undertaken the 863 Program of the Ministry of Science and Technology, the National Science and Technology Support Plan, the High-tech Industrialization Project of the National Development and Reform Commission, the Major Science and Technology Project of Henan Province, and the Luoyang City Science and Technology Project. There are nearly 40 major scientific and technological projects at the national, provincial and municipal levels, such as major special projects; as of December 2023, a total of 64 new veterinary drug certificates have been obtained, and 4 national key new products have been certified; 546 invention patents have been applied for and invention patents have been obtained It has 312 authorizations, including 32 international invention patents, more than 20 national, provincial and municipal science and technology achievement awards, and 3 China Patent Excellence Awards. It has become a scientific and technological innovation enterprise in the domestic animal medicine industry.

In recent years, the company has made significant breakthroughs in industrialization technologies such as reverse genetic technology, bacterial artificial chromosome, prokaryotic and eukaryotic expression technology, high-density cell suspension culture technology, high-density fermentation and antigen extraction, concentration and purification technology, etc. It is at the leading level in product structure innovation, such as genetic engineering vaccines and macrolide animal-specific antibiotics.

Among them, the Newcastle Disease, Infectious Bronchitis and Avian Influenza inactivated Vaccine (Strain Re-9) have led the Chinese subtype H9 avian influenza vaccine into the era of genetically engineered vaccines. The genetic engineering subunit vaccine of pure virus-like granular porcine circovirus type 2 and the combined vaccine of mycoplasma and circovirus with aqueous adjuvant for swine, which have been successfully developed over 7 years, has been launched on the market, leading the iterative upgrade of porcine circovirus vaccine in the industry.

In 2019, the mutant strain of porcine pseudorabies inactivated vaccine (HN1201-ΔgE strain) was successfully launched, which will make a positive contribution to the prevention, control and purification of porcine pseudorabies in China.

In 2022, the Classical Swine Fever Virus E2 Protein Recombinant Baculovirus Vaccine， Inactivated(Strain Rb–03) Wenkejing, was launched shockingly, leading a new era of swine fever prevention and control.

In 2023, the porcine circovirus type 2 and Mycoplasma hyopneumoniae inactivated vaccine Xin Yuan Zhi was launched gloriously. Provide strong technical and product support for the in-depth prevention and control and comprehensive purification of pig diseases in my country.

Pulike adheres to the purpose of "Golden quality, benefit mankind", follows the development concept of "Innovation creates future", abides by the development strategy of "Decent and prudent operation", carries forward the enterprise spirit of "Integrity and pragmatism, first class orientation". Pursuing research, production and promotion of new veterinary vaccines and drugs with high starting point and high standard, committed to building a world brand in the Chinese animal health product industry.